-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster II

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Adult, Anemias, antibodies, Biological, Coronaviruses, SARS-CoV-2/COVID-19, sickle cell disease, Animal models, bioengineering, Diseases, Non-Biological, sickle cell trait, Therapies, red blood cells, Hemoglobinopathies, Technology and Procedures, Cell Lineage, Study Population, Clinically relevant, Quality Improvement
Sunday, December 6, 2020: 7:00 AM-3:30 PM

Dipti Gupta1,2, Yannis Hara, PhD1*, Samuel Lessard, PhD1*, Sarah Sturtevant, BSc1*, Yukio Nakamura, MD, PhD3*, Sriram Krishnamoorthy, PhD1, Melanie Demers, PhD1* and Alexandra Hicks, PhD1*

1Rare Blood Disorders, Sanofi, Waltham, MA
2Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL
3Cell Engineering Division, RIKEN BioResource Research Center, Tsukuba, Japan

Kobina Dufu, PhD*, Carsten Alt, MSc, PhD*, Steven Strutt, PhD*, Tzechiang Tang*, Hilary Liao-Zou*, Yue Yuan*, Brian E Cathers, PhD* and Donna Oksenberg, PhD

Global Blood Therapeutics, South San Francisco, CA

Anu Marahatta, PhD1, Jonathan M. Flanagan, PhD2, Thad A. Howard, MS3*, Nicole Mortier, MHS, PA-C4*, William Schultz, MHS, PA1*, Kathryn L McElhinney, BS1*, Leon Tshilolo, MD PhD5*, Thomas N. Williams, MD PhD6*, Peter Olupot-Olupot, MD PhD7*, Brigida Santos, MD8*, Chandy C. John, MD, MS9*, Robert Opoka, MMED10*, Rosa M. Nieves, MD11*, Rafael Mena, MD12*, Marvin E Reid, MB, BS, PhD13*, Angela Rankine-Mullings, MBBS14*, Jasmine Baker, PhD2, Patrick T. McGann, MD15,16, Banu Aygun, MD17, Adam Lane, PhD18*, George A. Tomlinson, PhD, BSc, MSc19*, Teresa Latham, MA1*, Susan E. Stuber, MA1* and Russell E. Ware, MD, PhD1,16

1Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
2Department of Pediatrics - Hematology/Oncology, Baylor College of Medicine, Houston, TX
3Division of Hematology, Cincinnati Children's Research Hospital, Cincinnati, OH
4George Washington University, Washington DC
5Centre Hospitalier Monkole, Kinshasa, Congo (The Democratic Republic of the)
6KEMRI-Wellcome Trust Programme, Kilifi, Kenya
7Mbale Clinical Research Institute, Mbale, Uganda
8Hospital Pediatrico David Bernardino, Luanda, Angola
9Ryan White Center for Pediatric Infectious Diseases and Global Health, Indiana University, Indianapolis, IN
10Pediatrics and Child Health, Makerere University, Kampala, Uganda
11Robert Reid Cabral Hospital, Santo Domingo, Dominican Republic
12Centro de Obstetricia y Ginecología, Santo Domingo, Dominican Republic
13Caribbean Institute for Health Research, University of the West Indies, Kingston, Jamaica
14Caribbean Institute for Health Research, Sickle Cell Unit, University of the West Indies, Kingston, Jamaica
15Division of Hematology, Children's Hospital Medical Center, Cincinnati, OH
16Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
17Pediatric Hematology Oncology and Stem Cell Transplantation, Cohen Children's Medical Center, New Hyde Park, NY
18Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
19Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada

Danitza Nebor, PhD1*, Celeste K. Kanne, BA1*, Mira Pochron, PhD2*, Donna Oksenberg, PhD2 and Vivien A. Sheehan, MD, PhD1

1Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX
2Global Blood Therapeutics, South San Francisco, CA

Xin Geng1*, Radu Mihaila1*, Yue Yuan1*, Steven Strutt, PhD1*, Jörg Benz2*, Tzechiang Tang1*, Christina Mayer, PharmD1* and Donna Oksenberg, PhD1

1Global Blood Therapeutics, South San Francisco, CA
2F. Hoffmann-La Roche AG, Basel, Switzerland

Celeste K. Kanne, BA1*, Danielle Guffey, MS2*, Charles Minard, PhD2*, Eduard van Beers, MD, PhD3*, Richard van Wijk, PhD4*, Minke A.E. Rab, MD5* and Vivien A. Sheehan, MD, PhD1

1Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX
2Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX
3Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
4Laboratory of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, Netherlands
5Department of Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, Utrecht, Netherlands

Gonzalo De Luna1*, Nicolas Lemonier, MD1*, Alexis Aidan, MD2*, Lea Bontemps, MD2*, Manuel Hautefaye, MD2*, Hadrien Diakonoff, MD2*, Cecile Aubrun1*, Anne-Laure Pham Hung D'Alexandry D'Orengiani, PhD2*, Dora Bachir, MD3,4*, Françoise Driss, MD2*, Amna Jebali, MD2*, Anoosha Habibi, MD, PhD5* and Pablo Bartolucci, MD, PhD6*

1APHP Hôpital Henri Mondor, Creteil, France
2APHP Hôpital Henri Mondor, Créteil, France
3Hôpital Henri Mondor, Creteil, FRA
4Sickle Cell Disease Center, Créteil, FRA
5Hopital Henri Mondor, Creteil Cedex, France
6Sickle cell referral center, Internal Medicine Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Creteil, France

Xu Zhang, PhD1*, Binal N. Shah, PhD1*, Taif Hassan1*, Sergei Nekhai, PhD2, Roberto Machado, MD3* and Victor R. Gordeuk, MD4

1Department of Medicine, University of Illinois at Chicago, Chicago, IL
2Center for Sickle Cell Disease and Department of Medicine, Howard University, Washington, DC
3Department of Medicine, Indiana University, Indianapolis, IN
4Sickle Cell Center, Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL

Ran An, PhD1, Yuncheng Man1*, Erdem Kucukal, PhD1*, Kevin Cheng1*, William Wulftange1*, Jane A. Little, MD2 and Umut A. Gurkan, PhD1

1Case Western Reserve University, Cleveland, OH
2University of North Carolina at Chapel Hill, Chapel Hill, NC

Yamna Ouchtar1*, Christian Kassasseya, MD2*, Kene Sekou, MD3*, Anne-Laure Pham Hung D'Alexandry D'Orengiani, PhD4*, Mehdi Kellaf, MD, PhD5*, Dapa Aly Diallo, MD, PhD3*, Laurent Najman, PhD1* and Pablo Bartolucci, MD, PhD6*

1ESIEE Paris, Paris, France
2IMRB – Inserm U955 Transfusion et maladies du globule rouge (Equipe 2) Etablissement Français du Sang, APHP Henri Mondor Hospital, Créteil, France
3Centre de Recherche et de Lutte contre la Drépanocytose (CRLD), Bamako, Mali
4APHP Hôpital Henri Mondor, Créteil, France
5Emergency Department, APHP Henri Mondor hospital, Créteil, France
6Sickle cell referral center, Internal Medicine Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Creteil, France

Jaime Luis Betancourt, MSN, NP1*, Shuo You, MD, PhD2*, Sean Campbell3*, Sabrina Pink1*, Merin Thomas, NP4*, Susanna A Curtis, MD, MS5 and Caterina P. Minniti, MD6

1Montefiore Medial Center, Nyack, NY
2Albert Einstein College of Medicine, Bronx, NY
3Montefiore Medical Center, New York, NY
4Department of Hematology, Montefiore Medical Center, Bronx, NY
5Montefiore Health Systems, Truckee, CA
6Division of Hematology, Montefiore Medical Center.Albert Einstein College of Medicine, Bronx, NY

*signifies non-member of ASH